GT BIOPHARMA INC (GTBP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.98+14.13%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Regain Nasdaq compliance by November 16, 2026: Compliance deadline 2026-11-16; stock $5.98 vs $1.00 target.
GT Biopharma aims to regain Nasdaq compliance by November 2026. It plans to start a phase 1a/1b trial for GTB-5550. These steps could improve its business outlook. The company is working to fix past problems.
The company is losing money and has weak management. It faces Nasdaq delisting risks. Clinical trials may fail or be delayed. These risks could hurt the stock.
The market expects continued losses and regulatory risks. There is no clear price target or growth forecast. Our view is cautious due to the company's weak financials and uncertain outlook.
Breaks if: trial not started or delayed beyond 2026
Begin phase 1a/1b clinical trial for GTB-5550 under an Investigator Initiated Clinical Trial Agreement with University of Minnesota.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious, as the company is loss-making and has a history of volatile management performance.
The market appears to be pricing in a high level of risk, given the company's loss-making status and recent financial performance that lags behind its peers. Expectations are low, particularly with a high probability of an earnings miss in the near term.
Fundamentals are likely to remain weak in the near term, as the company has not shown financial improvement and has a high miss probability for upcoming earnings. Management's focus on regaining Nasdaq compliance and initiating clinical trials is still in early stages, with limited impact on financials.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, which could influence GTBP's trajectory. Additionally, the company's ability to regain Nasdaq compliance and successfully initiate clinical trials will be critical.
The most important moves since the prior daily snapshot.
Total stock risk fell by 10.4 points (from 90.6 to 80.2).
No, our read on the company is unchanged. The total stock risk score fell. Recent financial performance remains below its industry cohort. There is no evidence of regained compliance with Nasdaq by the November deadline.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q2. The company entered a clinical trial agreement to initiate phase 1a/1b trials for GTB-5550. No revenue or operating income impact is yet reported; the priority is in early stages with limited financial delivery so far.
“Entered agreement with University of Minnesota to sponsor IND and phase 1a/1b clinical trial for GTB-5550.”
Breaks if: losses worsen or cash flow remains negative
Breaks if: failure to regain Nasdaq compliance by November 2026
Achieve compliance with Nasdaq Listing Rule 5550(a)(2) by November 16, 2026 to avoid delisting.
Newly stated in 2026-Q2. The company was granted a 180-day extension until November 16, 2026 to regain compliance with Nasdaq listing rules. There is no financial improvement evidence yet; the priority is newly stated and the trajectory is pending.
“Received letter granting additional compliance period until November 16, 2026 to regain Nasdaq compliance.”
Over the next 1 to 3 years, GTBP's outlook remains uncertain due to high risk and management volatility. Not investment advice.